叉头框蛋白M1在脑胶质瘤中作用的研究进展

doi:10.16352/j.issn.1001-6325.2023.10.1604

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (10): 1604-1607.doi: 10.16352/j.issn.1001-6325.2023.10.1604

叉头框蛋白M1在脑胶质瘤中作用的研究进展

侯欣然, 厚静雅, 张亚茹, 李海丽^*

山东第一医科大学(山东省医学科学院) 临床与基础医学院(基础医学研究所),山东济南 250000

收稿日期:2023-01-10 修回日期:2023-05-04 出版日期:2023-10-05 发布日期:2023-10-05
通讯作者: *lihaili@sdfmu.edu.cn
基金资助:
山东省自然科学基金(ZR2021QH242);临床医学卓越班本科生科技创新计划(KC2020-008);大学生创新创业训练计划(2022104391692)

Research progress on the role of forkhead box protein M1 in brain glioma

HOU Xinran, HOU Jingya, ZHANG Yaru, LI Haili^*

School of Clinical and Basic Medical Sciences/Institute of Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250000, China

Received:2023-01-10 Revised:2023-05-04 Online:2023-10-05 Published:2023-10-05
Contact: *lihaili@sdfmu.edu.cn

摘要/Abstract

摘要： 胶质瘤是成人中枢神经系统中最常见的原发性肿瘤。叉头框蛋白M1(FOXM1)是叉头框转录因子家族的成员之一,其可通过调控Wnt/β-catenin、Akt/FOXM1、p53通路及其自身的翻译后修饰过程促进神经胶质瘤的恶性增殖、迁移和侵袭等过程。本文总结叉头框蛋白M1在脑胶质瘤中的作用,以期为临床脑胶质瘤的治疗提供新的理论依据和治疗靶标。

关键词: 叉头框蛋白M1(FOXM1), 胶质瘤, Wnt/β-catenin, Akt/FOXM1, p53通路

Abstract: Glioma is the most common primary tumor found in central nervous system of adult patients. The forkhead box protein M1 (FOXM1) is a member of the forkhead box transcription factor family, which can regulate Wnt/β-Catenin, Akt/FOXM1, p53 pathways and their own post-translational modification processes promote the malignant proliferation, migration, and invasion of glioma. These results of research provide new theoretical basis and therapeutic targets for the clinical treatment of glioma.

Key words: forkhead box protein M1(FOXM1), glioma, Wnt/β-catenin, Akt/FOXM1, p53 pathway

中图分类号:

R730.264

侯欣然, 厚静雅, 张亚茹, 李海丽. 叉头框蛋白M1在脑胶质瘤中作用的研究进展[J]. 基础医学与临床, 2023, 43(10): 1604-1607.

HOU Xinran, HOU Jingya, ZHANG Yaru, LI Haili. Research progress on the role of forkhead box protein M1 in brain glioma[J]. Basic & Clinical Medicine, 2023, 43(10): 1604-1607.

参考文献

[1]Klinhom-On N, Seubwai W, Sawanyawisuth K, et al. FOXM1c is the predominant FOXM1 isoform expressed in cholangiocarcinoma that associated with metastatic poten-tial and poor prognosis of patients[J]. Heliyon, 2021, 7: e06846.doi: 10.1016/j.heliyon.2021.e06846.
[2]Shim JK, Lim SH, Jeong JH, et al. A lignan from Alnus japonica inhibits glioblastoma tumorspheres by suppression of FOXM1[J]. Sci Rep, 2022, 12: 13990.doi: 10.1038/s41598-022-18185-w.
[3]Patel AJ, Wan YW, Al-Ouran R, et al. Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors[J]. Proc Natl Acad Sci U S A, 2019, 116: 21715-21726.
[4]Yi L, Wang H, Li W, et al. The FOXM1/RNF26/p57 axis regulates the cell cycle to promote the aggressiveness of bladder cancer[J]. Cell Death Dis, 2021, 12: 944.doi: 10.1038/s41419-021-04260-z.
[5]Uxa S, Castillo-Binder P, Kohler R, et al. Ki-67 gene expression[J]. Cell Death Differ, 2021, 28: 3357-3370.
[6]Fu J, Peng J, and Tu G Knockdown MTDH inhibits glioma proliferation and migration and promotes apoptosis by downregulating MYBL2[J]. Mediators Inflamm, 2022, 2022: 1706787.doi: 10.1155/2022/1706787.
[7]Zhao P, Li T, Wang Y, et al. LncRNA MYCNOS promotes glioblastoma cell proliferation by regulating miR-216b/FOXM1 axis[J]. Metab Brain Dis, 2021, 36: 1185-1189.
[8]Tao W, Zhang A, Zhai K, et al. SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expres-sion in glioma stem cells[J]. EMBO Mol Med, 2020, 12: e12291.doi: 10.15252/emmm.202012291.
[9]Sher G, Masoodi T, Patil K, et al. Dysregulated FOXM1 signaling in the regulation of cancer stem cells[J]. Semin Cancer Biol, 2022, 86: 107-121.
[10]Zhang N, Wei P, Gong A, et al. FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis[J]. Cancer Cell, 2011, 20: 427-42.
[11]Liu W, Shen D, Ju L, et al. MYBL2 promotes prolifera-tion and metastasis of bladder cancer through transactivation of CDCA3[J]. Oncogene, 2022, 41: 4606-4617.
[12]Chen L, Xu Z, Li Q, et al. USP28 facilitates pancreatic cancer progression through activation of Wnt/β-catenin pathway via stabilising FOXM1[J]. Cell Death Dis, 2021, 12: 887.doi: 10.1038/s41419-021-04163-z.
[13]Hashemi M, Etemad S, Rezaei S, et al. Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: revisiting molecular interactions[J]. Biomed Pharmacother, 2023, 158: 114204.doi: 10.1016/j.biopha.2022.114204.
[14]Xu K, Zhang K, Ma J, et al. CKAP4-mediated activation of FOXM1 via phosphorylation pathways regulates malig-nant behavior of glioblastoma cells[J]. Transl Oncol, 2023, 29: 101628.doi: 10.1016/j.tranon.2023.101628.
[15]Kimura H, Sada R, Takada N, et al. The Dickkopf1 and FOXM1 positive feedback loop promotes tumor growth in pancreatic and esophageal cancers[J]. Oncogene, 2021, 40: 4486-4502.
[16]Fu Y, Bai C, Wang S, et al. AKT1 phosphorylates RBM17 to promote Sox2 transcription by modulating alternative splicing of FOXM1 to enhance cancer stem cell properties in colorectal cancer cells[J]. FASEB J, 2023, 37: e22707.doi: 10.1096/fj.202201255R.
[17]Zhang X, Lv QL, Huang YT, et al. Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma[J]. J Exp Clin Cancer Res, 2017, 36: 105.doi: 10.1186/s13046-017-0573-6.
[18]Levine AJ p53: 800 million years of evolution and 40 years of discovery[J]. Nat Rev Cancer, 2020, 20: 471-480.
[19]Kennedy MC, Lowe SW. Mutant p53: it's not all one and the same[J]. Cell Death Differ, 2022, 29: 983-987.
[20]Kumari R, Hummerich H, Shen X, et al. Simultaneous expression of MMB-FOXM1 complex components enables efficient bypass of senescence[J]. Sci Rep, 2021, 11: 21506.doi: 10.1038/s41598-021-01012-z.
[21]Jia J, Cui Y, Tan Z, et al. Transcriptional factor FoxM1-activated microRNA-335-3p maintains the self-renewal of neural stem cells by inhibiting p53 signaling pathway via Fmr1[J]. Stem Cell Res Ther, 2021, 12: 169.doi: 10.1186/s13287-021-02191-2.
[22]Tanaka N, Zhao M, Tang L, et al. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1[J]. Oncogene, 2018, 37: 1279-1292.
[23]Zhang W, Qian W, Gu J, et al. Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer[J]. Cancer Lett, 2023, 552: 215976.doi: 10.1016/j.canlet.2022.215976.
[24]Bollu LR, Shepherd J, Zhao D, et al. Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1[J]. NPJ Breast Cancer, 2020, 6: 2.doi: 10.1038/s41523-019-0143-5.
[25]黄博, 程苾恒, 解美婷, 等. FOXM1促进子宫内膜癌细胞系HEC-1B增殖、迁移和侵袭[J]. 基础医学与临床, 2021, 41: 1780-1785.

叉头框蛋白M1在脑胶质瘤中作用的研究进展

Research progress on the role of forkhead box protein M1 in brain glioma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张迪雅, 李云帆, 郭泓江, 仇佳星, 王钰铖, 鞠瑞, 郭磊. 胶质瘤条件培养基促进巨噬细胞糖酵解及表型转化[J]. 基础医学与临床, 2024, 44(5): 599-605.
[2]	赵晓琦, 董鑫, 刘聪, 任鹏程, 张亮. 丙泊酚促进绝经后骨质疏松大鼠血管生成[J]. 基础医学与临床, 2023, 43(10): 1530-1536.
[3]	蒲超, 张珊珊, 吴青霞, 罗栩伟, 王亮, 张波. Lnc000727促进人骨髓间充质干细胞向成骨细胞分化[J]. 基础医学与临床, 2022, 42(7): 1047-1052.
[4]	唐婉军, 彭小忠, 韩为. IDH1调控干扰素通路相关基因IFIT3的表达[J]. 基础医学与临床, 2021, 41(7): 988-994.
[5]	李琪, 张小强, 陶一凡, 朱孟雯, 崔丹丹, 孙腾腾. 原花青素抑制Aβ_25-35诱导的人神经母细胞瘤细胞系SH-SY5Y分泌Aβ_1-42[J]. 基础医学与临床, 2021, 41(5): 704-708.
[6]	方黄毅, 尤朝国, 庞晨, 章钟鼎, 张哲, 况统帅, 盛汉松. FM19G11体外增敏替莫唑胺对MGMT阳性恶性胶质瘤细胞系的作用机制[J]. 基础医学与临床, 2021, 41(4): 514-520.
[7]	张宁, 马辉辉, 王凡, 梁伟, 汪义纯, 吴炳山, 李庆新. 脑胶质瘤患者MGMT启动子甲基化和IDH1突变与临床预后相关[J]. 基础医学与临床, 2021, 41(10): 1476-1480.
[8]	邢靖松, 克甜甜, 张琳, 梁东, 张桐, 高尚锋. Spinophilin在神经系统疾病中的研究进展[J]. 基础医学与临床, 2021, 41(10): 1507-1509.
[9]	李晶, 崔宏伟, 杨凌. microRNA通过ROS途径对脑胶质瘤调节机制的研究进展[J]. 基础医学与临床, 2020, 40(8): 1124-1129.
[10]	汪秀梅, 王康康, 陈晓燕, 罗金键. 二氢丹参酮Ⅰ促进人食管鳞癌细胞系EC9706凋亡[J]. 基础医学与临床, 2020, 40(7): 955-959.
[11]	孙茂苍, 李鑫. miR-107抑制胶质瘤细胞的体外增殖、迁移和侵袭[J]. 基础医学与临床, 2020, 40(6): 784-789.
[12]	张美莲, 王志星, 胡艳, 冉坤念, 韩为, 彭小忠. RNA结合蛋白作为氯福克酚药靶的机制初探[J]. 基础医学与临床, 2020, 40(5): 621-626.
[13]	王晓艳, 杜虹, 王伟, 权会琴. 乙型肝炎病毒X蛋白抑制肝癌细胞系中DKK2的表达[J]. 基础医学与临床, 2020, 40(10): 1348-1352.
[14]	卫群芳朱丽媛韩为彭小忠. 胶质瘤中PTB调控长非编码RNA选择性剪接的筛选[J]. 基础医学与临床, 2018, 38(6): 787-792.
[15]	孙莹梁晓春刘伟刘頔. 筋脉通含药血清对高糖培养大鼠雪旺细胞β-catenin、GSK-3β及髓鞘零蛋白表达的影响[J]. 基础医学与临床, 2017, 37(4): 484-487.